Skip to content

Steve Arkinstall

Steve Arkinstall

Company: Elstar Therapeutics

Job title: President & CEO


Dr Steve Arkinstall obtained his PhD from the University of Oxford and has over 25 years of experience in bio-pharmaceutical drug discovery research across a range of disease areas and technology platforms. Previously, he worked at the prestigious Glaxo Institute for Molecular Biology in Geneva, Switzerland, where he studied novel disease mechanisms in several therapeutic indications including cancer and inflammatory diseases. Steve went on to serve as the President of the Serono Research Institute in Boston with a focus on oncology drug discovery delivering a number of molecules for clinical development. After Serono was acquired by Merck KGaA, Steve took on several leadership roles including antibody discovery and protein engineering. More recently, Steve served as the Chief Scientific Officer at Kymab, a British biotechnology company built on a proprietary mouse antibody platform and focused on oncology and inflammatory diseases. Now, as the CEO of Elstar, and as a cancer survivor himself, Steve’s passion is to build a portfolio of multi-functional immunotherapeutic drugs to treat patients suffering from life-threatening cancers unaddressed by existing treatments.


A New Concept for Cancer Immunotherapies with Robust Efficacy and Minimal Toxicity 9:00 am

Elstar’s molecules are built to target tumors through binding simultaneously two cell surface antigens allowing precision delivery of one or more of our immune engager modules. Our non-CD3 T cell engager drives expansion and activation of a discrete T cell population without generating cytokines responsible for CRS We also have developed a new generation of…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.